Ibrutinib Patent Expiration
Ibrutinib is used for treating various types of leukemias, lymphomas, and graft-versus-host disease, including those with specific genetic deletions. It was first introduced by Pharmacyclics Llc
Ibrutinib Patents
Given below is the list of patents protecting Ibrutinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Imbruvica | US10004746 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US10004746 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10010507 | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Mar 03, 2036 | Pharmacyclics Llc |
| Imbruvica |
US10010507 (Pediatric) | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Sep 03, 2036 | Pharmacyclics Llc |
| Imbruvica | US10016435 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US10016435 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10106548 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10106548 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10125140 | Crystalline forms of a bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10125140 (Pediatric) | Crystalline forms of a bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10213386 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Mar 03, 2036 | Pharmacyclics Llc |
| Imbruvica |
US10213386 (Pediatric) | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Sep 03, 2036 | Pharmacyclics Llc |
| Imbruvica | US10294231 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10294231 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10294232 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10294232 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10463668 | Methods of treating and preventing graft versus host disease | Oct 24, 2034 | Pharmacyclics Llc |
| Imbruvica |
US10463668 (Pediatric) | Methods of treating and preventing graft versus host disease | Apr 24, 2035 | Pharmacyclics Llc |
| Imbruvica | US10478439 | Use of inhibitors of bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US10478439 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10653696 | Use of inhibitors of bruton's tyrosine kinase (BTK) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US10653696 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (BTK) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10695350 | Methods of treating and preventing graft versus host disease | Oct 24, 2034 | Pharmacyclics Llc |
| Imbruvica |
US10695350 (Pediatric) | Methods of treating and preventing graft versus host disease | Apr 24, 2035 | Pharmacyclics Llc |
| Imbruvica | US10751342 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US10751342 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10752634 | Crystalline forms of a brutons tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10752634 (Pediatric) | Crystalline forms of a brutons tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10828259 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Mar 03, 2036 | Pharmacyclics Llc |
| Imbruvica |
US10828259 (Pediatric) | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Sep 03, 2036 | Pharmacyclics Llc |
| Imbruvica | US10961251 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10961251 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US11672803 | Use of inhibitors of Brutons tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US7514444 | Inhibitors of bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US7514444 (Pediatric) | Inhibitors of bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8008309 | Inhibitors of bruton's tyrosine kinase | Nov 13, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8008309 (Pediatric) | Inhibitors of bruton's tyrosine kinase | May 13, 2028 | Pharmacyclics Llc |
| Imbruvica | US8476284 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US8476284 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8497277 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US8497277 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8563563 | Inhibitors of bruton's tyrosine kinase | Apr 26, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8563563 (Pediatric) | Inhibitors of bruton's tyrosine kinase | Oct 26, 2027 | Pharmacyclics Llc |
| Imbruvica | US8697711 | Inhibitors of bruton'S tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US8697711 (Pediatric) | Inhibitors of bruton'S tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8703780 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US8703780 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8735403 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US8735403 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8754090 | Use of inhibitors of bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US8754090 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US8754091 | Inhibitors of bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US8754091 (Pediatric) | Inhibitors of bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8952015 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US8952015 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8957079 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US8957079 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8999999 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US8999999 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US9125889 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US9125889 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US9181257 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica |
US9181257 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US9296753 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Oct 30, 2033 | Pharmacyclics Llc |
| Imbruvica |
US9296753 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Apr 30, 2034 | Pharmacyclics Llc |
| Imbruvica | US9540382 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Aug 18, 2033 | Pharmacyclics Llc |
| Imbruvica |
US9540382 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Feb 18, 2034 | Pharmacyclics Llc |
| Imbruvica | US9655857 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Mar 03, 2036 | Pharmacyclics Llc |
| Imbruvica |
US9655857 (Pediatric) | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Sep 03, 2036 | Pharmacyclics Llc |
| Imbruvica | US9713617 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US9713617 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US9725455 | Crystalline forms of a bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US9725455 (Pediatric) | Crystalline forms of a bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US9795604 | Methods of treating and preventing graft versus host disease | Oct 24, 2034 | Pharmacyclics Llc |
| Imbruvica |
US9795604 (Pediatric) | Methods of treating and preventing graft versus host disease | Apr 24, 2035 | Pharmacyclics Llc |
| Imbruvica | US9801881 | Use of inhibitors of bruton's tyrosine kinase (BTK) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US9801881 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (BTK) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US9801883 | Use of inhibitors of bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US9801883 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US9814721 | Use of inhibitors of bruton'S tyrosine kinase (BTK) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US9814721 (Pediatric) | Use of inhibitors of bruton'S tyrosine kinase (BTK) | Dec 03, 2031 | Pharmacyclics Llc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Ibrutinib Generics
Several generic applications have been filed for Ibrutinib.
Given below is the list of companies who have filed for Ibrutinib generic.
1. ZYDUS
Zydus Worldwide Dmcc has filed for 2 different strengths of generic version for Ibrutinib. Given below are the details of the strengths of this generic introduced by Zydus.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 70MG | capsule | Discontinued | ORAL | N/A | Mar 31, 2021 |
| 140MG | capsule | Discontinued | ORAL | N/A | Mar 31, 2021 |